Background The increased adoption of the internet, social media, wearable devices, e-
health services, and other technology-driven services in medicine and healthcare has led to …

Drug survival studies have been utilized to evaluate the real-world effectiveness of biologics
used in psoriasis. However, the increasing volume of drug survival data suffers from large …

Background Drug survival rates reflect efficacy and safety and may be influenced by the
availability of alternative treatment options. Little is known about time‐dependent drug …

Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of worldwide
population, and causing long-term troubles to the patients. Therefore, it is urgent to develop …

Psoriasis is a most common chronic autoimmune-arbitrated cutaneous inflammatory skin
disorder by unclear pathogenesis. In this current study we demonstrated the effect of …

Despite the large number of biologics currently available for moderate-to-severe psoriasis,
poor adherence and persistence to therapy represent the main issues for both the clinical …

Abstract Background and Objective The most recently approved biologics for moderate-to-
severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently …

Psoriasis is a chronic autoimmune disease affecting skin which may also manifest in nails
and joints. Several biologic treatments have been approved in Japan for psoriasis. Each …

The purpose of this study was to investigate the protective effects of ambroxol in psoriasis-
like skin inflammation both in vitro and in vivo and delineate the molecular mechanism of …

The real‐world treatment landscape for patients with moderate‐to‐severe psoriasis
receiving systemic therapies in Japan is not well understood. This study describes the …